WO2000076500A3 - Compound for use as a medicament for treatment of disorders involving bronchocontraction - Google Patents

Compound for use as a medicament for treatment of disorders involving bronchocontraction Download PDF

Info

Publication number
WO2000076500A3
WO2000076500A3 PCT/SE2000/001267 SE0001267W WO0076500A3 WO 2000076500 A3 WO2000076500 A3 WO 2000076500A3 SE 0001267 W SE0001267 W SE 0001267W WO 0076500 A3 WO0076500 A3 WO 0076500A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
compound
treatment
disorders involving
bronchocontraction
Prior art date
Application number
PCT/SE2000/001267
Other languages
French (fr)
Other versions
WO2000076500A2 (en
WO2000076500A8 (en
Inventor
Staffan Skogvall
Original Assignee
Respiratorius Ab
Staffan Skogvall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902251A external-priority patent/SE9902251D0/en
Priority claimed from SE9902252A external-priority patent/SE9902252D0/en
Priority claimed from PCT/SE2000/000819 external-priority patent/WO2000064441A2/en
Priority to JP2001502833A priority Critical patent/JP2003501462A/en
Priority to EP00944534A priority patent/EP1185263A2/en
Priority to AU58619/00A priority patent/AU5861900A/en
Application filed by Respiratorius Ab, Staffan Skogvall filed Critical Respiratorius Ab
Priority to PCT/SE2000/002613 priority patent/WO2001095903A1/en
Priority to AU2001225663A priority patent/AU2001225663A1/en
Priority to PCT/SE2000/002612 priority patent/WO2001095902A1/en
Priority to AU2001225664A priority patent/AU2001225664A1/en
Publication of WO2000076500A2 publication Critical patent/WO2000076500A2/en
Publication of WO2000076500A3 publication Critical patent/WO2000076500A3/en
Publication of WO2000076500A8 publication Critical patent/WO2000076500A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a compound having agonist activity to the 5-HT4 receptor for use as a medicament and to the use of said compounds in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving bronchocontraction of a human or animal body, as well as methods of treatment, wherein said compounds are administered. The present invention also relates to a compound having antagonist activity to the 5-HT3 receptor for use as a medicament and to the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving bronchocontraction of a human or animal body, as well as methods of treatment, wherein said compounds are administered.
PCT/SE2000/001267 1999-06-15 2000-06-15 Compound for use as a medicament for treatment of disorders involving bronchocontraction WO2000076500A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2001502833A JP2003501462A (en) 1999-06-15 2000-06-15 Receptor agonists and antagonists
EP00944534A EP1185263A2 (en) 1999-06-15 2000-06-15 Receptor agonists and antagonists
AU58619/00A AU5861900A (en) 1999-06-15 2000-06-15 Receptor agonists and antagonists
AU2001225664A AU2001225664A1 (en) 2000-06-15 2000-12-20 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
PCT/SE2000/002612 WO2001095902A1 (en) 2000-06-15 2000-12-20 A composition comprising a combination of receptor agonists and antagonists
PCT/SE2000/002613 WO2001095903A1 (en) 2000-06-15 2000-12-20 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
AU2001225663A AU2001225663A1 (en) 2000-06-15 2000-12-20 A composition comprising a combination of receptor agonists and antagonists

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
SE9902252-7 1999-06-15
SE9902251-9 1999-06-15
SE9902251A SE9902251D0 (en) 1999-06-15 1999-06-15 Medical preparation
SE9902252A SE9902252D0 (en) 1999-06-15 1999-06-15 Medical preparation
US13963399P 1999-06-17 1999-06-17
US13963299P 1999-06-17 1999-06-17
US60/139,633 1999-06-17
US60/139,632 1999-06-17
SEPCT/SE00/00819 2000-04-28
PCT/SE2000/000819 WO2000064441A2 (en) 1999-04-28 2000-04-28 Compound for use as a medicament for treatment of disorders involving bronchocontraction

Publications (3)

Publication Number Publication Date
WO2000076500A2 WO2000076500A2 (en) 2000-12-21
WO2000076500A3 true WO2000076500A3 (en) 2001-07-12
WO2000076500A8 WO2000076500A8 (en) 2001-08-16

Family

ID=56290034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001267 WO2000076500A2 (en) 1999-06-15 2000-06-15 Compound for use as a medicament for treatment of disorders involving bronchocontraction

Country Status (5)

Country Link
EP (1) EP1185263A2 (en)
JP (1) JP2003501462A (en)
CN (1) CN1355698A (en)
AU (1) AU5861900A (en)
WO (1) WO2000076500A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918425D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
WO2001095902A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab A composition comprising a combination of receptor agonists and antagonists
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
CA2491797A1 (en) * 2002-07-10 2004-01-22 Warner-Lambert Company Llc Gastrointestinal compositions
US6986901B2 (en) 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
EP1902053B1 (en) * 2005-06-07 2011-01-12 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
GB0901487D0 (en) 2009-01-30 2009-03-11 Movetis N V Asthma Therapy
EP3261645B1 (en) 2015-02-27 2021-04-28 Dechra Limited Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004660A1 (en) * 1987-11-14 1989-06-01 Beecham Group Plc 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
SU1701320A1 (en) * 1988-03-29 1991-12-30 Рижский Медицинский Институт Method for stopping bronchial asthma paroxysms
US5418241A (en) * 1992-09-28 1995-05-23 Synthelabo Piperidine derivatives, their preparation and their application in therapeutics
WO1997017345A1 (en) * 1995-11-09 1997-05-15 Synthelabo 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004660A1 (en) * 1987-11-14 1989-06-01 Beecham Group Plc 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
SU1701320A1 (en) * 1988-03-29 1991-12-30 Рижский Медицинский Институт Method for stopping bronchial asthma paroxysms
US5418241A (en) * 1992-09-28 1995-05-23 Synthelabo Piperidine derivatives, their preparation and their application in therapeutics
WO1997017345A1 (en) * 1995-11-09 1997-05-15 Synthelabo 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BENOIT GENTIL ET AL.: "Droperidol prevents serotonin-induced bronchospasm in the guinea pig", ANESTH. ANALG., vol. 72, 1991, pages 612 - 615, XP002938846 *
D.T.T. CHUA ET AL.: "The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in orientals receiving cisplatin chemotherapy: a randomized crossover trial", BR. J. CLIN. PHARMACOL., vol. 41, 1996, pages 403 - 408, XP001006146 *
DATABASE CA [online] 17 August 1992 (1992-08-17), TAIVAN I.L. ET AL.: "Method for stopping bronochial asthma attack", XP002948473, accession no. STN Database accession no. 117:63015 *
ENRIQUE HONG ET AL.: "Similarities between the pharmacological actions of quipazine and serotonin", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 6, 1969, pages 274 - 280, XP002938849 *
F. GUERRIN ET AL.: "Effects du metoclopramide sur le bronchospasme experimental du cobaye et sur le test a l'acetylcholine chez l'homme", LILLE MEDICAL, vol. 16, no. 5, 1971, pages 731 - 735, XP002906226 *
J. SIMKE ET AL.: "Bradykinin induced bronchoconstriction in guinea pigs and its modification by various agents", ARCH. INT. PHARMACODYN., vol. 165, no. 2, 1967, pages 291 - 301, XP002906227 *
L.B. LIPHAM ET AL.: "Quipazine-metoclopramide inhibition of CB-154-induced prolactin suppression in rats: Neurotransmitter-metabolite correlations (42475)", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 184, 1987, pages 250 - 255, XP001062639 *
M.P. RECHTMAN ET AL.: "Effects of morphine, H-Tyr-D-Arg-Phe-Lys-NH2(DALDA) and B-HT920 on non-cholinergic nerve-mediated bronchoconstriction in pithed guinea-pigs", BR. J. PHARMACOL., vol. 101, 1990, pages 269 - 272, XP002938845 *
M.P. RECHTMAN: "Sensory nerves in the airways as a target for drug development", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 19, 1992, pages 31 - 39, XP002938844 *
N. OTOMO ET AL.: "In vivo assessment of droperidol-induced bronchial relaxation in dogs using a superfine fibreoptic bronchoscope", BRITISH JOURNAL OF ANAESTHESIA, vol. 78, 1997, pages 579 - 582, XP002938843 *
RICHARD A. STEINBROOK ET AL.: "Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron and droperidol plus metoclopramide", JOURNAL OF CLINICAL ANESTHESIA, vol. 10, 1998, pages 494 - 498, XP001004443 *
SHAHIN SANJAR ET AL.: "The effect of prophylactic anti-asthma drugs on PAF-induced airway hyperreactivity", JAPAN. J. PHARMACOL., vol. 51, 1989, pages 151 - 160, XP002938847 *
T.J. HEMNANI & P.G. DASHPUTRA: "Potentiation of the psychotropic effect of chlorpromazine by metoclopramide", INDIAN J. MED. RES., vol. 78, October 1983 (1983-10-01), pages 593 - 595, XP002940951 *
VITTORIO GEBBIA ET AL.: "Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study", ANTI-CANCER DRUGS, vol. 7, 1996, pages 734 - 737, XP002938130 *
YOSHIO TSUCHIYA ET AL.: "Inhibition of the vagal reflex-induced tracheal constriction by psychotropic drugs", J. PHARMACOBIO-DYN., vol. 12, 1989, pages 437 - 440, XP002938848 *

Also Published As

Publication number Publication date
AU5861900A (en) 2001-01-02
EP1185263A2 (en) 2002-03-13
WO2000076500A2 (en) 2000-12-21
WO2000076500A8 (en) 2001-08-16
JP2003501462A (en) 2003-01-14
CN1355698A (en) 2002-06-26

Similar Documents

Publication Publication Date Title
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
YU71901A (en) NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND beta-MIMETICS
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO1999017755A3 (en) Medicaments
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
WO2001005763A3 (en) Compounds with activity on muscarinic receptors
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2004067002A3 (en) SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
NO990433L (en) New compounds and compositions for the treatment of diseases associated with tryptase activity
HK1092135A1 (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo [3.2.0]heptane is an effective analgesic agent
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2004093881A3 (en) Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
HUP0200969A3 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders os mixed anxiety-depression disorders
WO2004026837A3 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
WO2002069944A3 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
IL151627A0 (en) Divided dose therapies with vascular damaging activity
WO2004002399A3 (en) Use of gaba-c receptor antagonists for the treatment of myopia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808979.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
ENP Entry into the national phase

Ref document number: 2001 502833

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000944534

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000944534

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10009559

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000944534

Country of ref document: EP